폐결핵 치료의 최신지견
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Sang-Won | - |
dc.contributor.author | Choi, Jae Chol | - |
dc.date.available | 2019-05-28T02:47:59Z | - |
dc.date.issued | 2019-01 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.issn | 2093-5951 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/18395 | - |
dc.description.abstract | Tuberculosis (TB) remains the world's leading cause of death from a single infectious disease. In addition, the incidence of TB is high in South Korea. Effective TB control requires early diagnosis and initiation of appropriate treatment. Therefore, it is very important for clinicians to understand evidence-based practical recommendations and to be familiar with up-to-date treatment regimens. In this review, we first describe anti-TB drugs, including new drugs. Secondly, we discuss the treatment of drug-susceptible TB. Finally, we present treatment strategies for drug-resistant TB, which is divided into isoniazid-resistant TB, rifampin-resistant TB, and multi-drug resistant TB. For the treatment of drug-susceptible TB, we recommend 2 months of 4 drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) followed by 4 months of 2 drugs (isoniazid and rifampin). For the treatment of isoniazid-resistant TB, we recommend 6 to 9 months of 4 drugs (rifampin, ethambutol, pyrazinamide, and levofloxacin or moxifloxacin). For the treatment of multi-drug resistant TB (MDR-TB), we recommend a minimum of 5 secondary drugs, including an injectable agent and quinolone. Although the World Health Organization recommended a shorter MDR-TB regimen in 2016, the Korean guidelines for tuberculosis have not yet accepted the shorter regimen. The treatment regimen of TB differs depending on the drug resistance pattern. Therefore, it is important to treat TB properly after confirming the drug resistance pattern. In addition, as new drugs are developed, new treatment guidelines for MDR-TB should be developed that are appropriate for circumstances in Korea. | - |
dc.format.extent | 12 | - |
dc.language | 일본어 | - |
dc.language.iso | JAP | - |
dc.publisher | KOREAN MEDICAL ASSOC | - |
dc.title | 폐결핵 치료의 최신지견 | - |
dc.title.alternative | Treatment of pulmonary tuberculosis | - |
dc.type | Article | - |
dc.identifier.doi | 10.5124/jkma.2019.62.1.25 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, v.62, no.1, pp 25 - 36 | - |
dc.identifier.kciid | ART002433335 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000456661700005 | - |
dc.identifier.scopusid | 2-s2.0-85060575520 | - |
dc.citation.endPage | 36 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 25 | - |
dc.citation.title | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.citation.volume | 62 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Tuberculosis | - |
dc.subject.keywordAuthor | Therapeutics | - |
dc.subject.keywordAuthor | Guideline | - |
dc.subject.keywordAuthor | Tuberculosis | - |
dc.subject.keywordAuthor | multidrug-resistant | - |
dc.subject.keywordAuthor | World Health Organization | - |
dc.subject.keywordPlus | DRUG-RESISTANT TUBERCULOSIS | - |
dc.subject.keywordPlus | MULTIDRUG-RESISTANT | - |
dc.subject.keywordPlus | ANTITUBERCULOSIS DRUG | - |
dc.subject.keywordPlus | DELAMANID | - |
dc.subject.keywordPlus | LEVOFLOXACIN | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | MOXIFLOXACIN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | MEROPENEM | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.